Timothy J. Schroeder is Director at Inmune Bio, Inc. (INMB). They have made 5 open-market trades across 1 company since 2021, most recently 2023-07-12.
CIK 0001767226
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| INMB | 82,187 | $129K |
Shares reported on the most recent Form 4, priced at the 2023-07-14 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| INMB | SELL · 10b5-1 | 2023-07-12 | 2023-07-14 | $11.01 | $110K | -22.7% | -25.4% | -35.4% |
| INMB | SELL | 2021-07-13 | 2021-07-14 | $27.63 | $800K | -31.3% | -29.8% | -22.0% |
| INMB | SELL | 2021-07-09 | 2021-07-12 | $23.21 | $696K | -7.5% | -33.3% | -25.3% |
| INMB | SELL | 2021-06-14 | 2021-06-15 | $19.02 | $190K | +6.4% | +23.3% | +7.9% |
| INMB | SELL | 2021-06-10 | 2021-06-14 | $17.01 | $340K | +3.8% | +23.2% | +3.8% |
| INMB | SELL | 2021-03-31 | 2021-04-01 | $11.95 | $120K | -4.9% | -3.5% | +41.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.